reslizumab · Medicine question

How does reslizumab reduce eosinophil survival and activity?

iatroX medicinesPublished 8 November 2026

The answer

Answer

Reslizumab binds specifically to interleukin-5 (IL-5), preventing its binding to its cell-surface receptor and blocking its biological function, thereby reducing eosinophil survival and activity.

Sources for this answer

Cinqaero (reslizumab) 10 mg/mL concentrate for solution for infusionTeva Pharmaceuticals Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 8Document updated 17 July 2023

Sources checked 8 November 2026

Explore this learning need in CPDTake this topic to CPD, then choose your learning context and available question library.

Do leukotriene antagonists or systemic corticosteroids affect the pharmacokinetics of reslizumab?How much sodium is in each 2.5 mL and 10 mL vial of Cinqaero (reslizumab)?Is it known whether reslizumab passes into human breast milk?What are the most frequently reported adverse reactions to reslizumab?What does Cinqaero (reslizumab) concentrate for solution for infusion look like?What does the product information recommend about reslizumab (Cinqaero) use during pregnancy?

loading page…

Answer

Sources for this answer

More questions about reslizumab

Answer

Sources for this answer

More questions about reslizumab

reslizumab

More clinical questions?